US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tharimmune Inc.

1.31

-0.0100-0.76%

Volume:6.30K

Turnover:8.28K

Market Cap:5.53M

PE:-0.14

High:1.32

Open:1.32

Low:1.31

Close:1.32

Loading ...

Overview Company News Filings

Tharimmune Inc. Files Prospectus for $1.74 Million Public Offering of Common Stock and Warrants

Tharimmune Inc. Announces $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Inc. Announces Immediate Resignation of Board Member Kelly Anderson

CEO Sireesh Appajosyula Reports Acquisition of Common Shares in Tharimmune Inc

Tharimmune Inc. Announces $2.5 Million Private Placement to Fund Clinical Development and Working Capital

Tharimmune Inc. Announces Key Leadership Appointments, Names Sireesh Appajosyula as CEO and James Gordon Liddy to Board

Tharimmune Inc. Announces Resignation of CFO Don Kim Due to Personal Reasons

BRIEF-Tharimmune - Randy Milby Resigns As CEO And Board Member

Tharimmune Inc. Announces Leadership Changes: Sireesh Appajosyula Appointed as CEO, James Gordon Liddy Joins Board

Tharimmune Inc. Held Its Annual Stockholders Meeting

Tharimmune Inc. Appoints Counter-Terrorism Expert James Gordon Liddy as Strategic Advisor for Opioid Defense Initiative

Director Sanam Parikh Reports Acquisition of Common Shares in Tharimmune Inc

Tharimmune Q1 EPS $(0.99) Up From $(2.55) YoY

BRIEF-Tharimmune Inc - Appoints Vincent Lopriore As Executive Chairman - SEC Filing

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

ACCESS Newswire

Tharimmune Inc. Expands Board to Nine Members, Appoints Clay Kahler and Gary Stetz

Tharimmune announces FDA feedback on TH104 for prophylaxis

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

ACCESS Newswire

Tharimmune Reports Preclinical Data for Dual-Target Biologics

MT Newswires Live

Tharimmune announces preclinical data from expanded pipeline with HS1940

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/THAR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"THAR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"THAR\",,,,,undefined,":{"symbol":"THAR","market":"US","secType":"STK","nameCN":"Tharimmune Inc.","latestPrice":1.31,"timestamp":1753972424139,"preClose":1.32,"halted":0,"volume":6304,"delay":0,"floatShares":3885500,"shares":4220920,"eps":-9.409598,"marketStatus":"Trading","change":-0.01,"latestTime":"07-31 10:36:59 EDT","open":1.32,"high":1.32,"low":1.31,"amount":8280.0278848,"amplitude":0.007576,"askPrice":1.32,"askSize":269,"bidPrice":1.3,"bidSize":65,"shortable":3,"etf":0,"ttmEps":-9.409598,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1753992000000},"marketStatusCode":2,"adr":0,"listingDate":1641963600000,"exchange":"NASDAQ","adjPreClose":1.32,"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.32,"latestTime":"19:49 EDT","volume":1668,"amount":2175.07,"timestamp":1753919340165},"volumeRatio":1.016322},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"THAR\",,,,,undefined,":{"symbol":"THAR","floatShares":3885500,"roa":"-149.70%","roe":"-400.44%","lyrEps":-9.409598,"volumeRatio":1.016322,"shares":4220920,"dividePrice":0,"high":1.32,"amplitude":0.007576,"preClose":1.32,"low":1.31,"week52Low":0.952,"pbRate":"-6.79","week52High":6.39,"institutionHeld":0,"latestPrice":1.31,"committee":-0.610778,"eps":-9.409598,"divideRate":0,"volume":6304,"delay":0,"ttmEps":-9.409598,"open":1.32,"prevYearClose":2.03,"prevWeekClose":1.494,"prevMonthClose":1.9402,"prevQuarterClose":1.9402,"fiveDayClose":1.53,"twentyDayClose":1.82,"sixtyDayClose":1.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"THAR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554772643","title":"Tharimmune Inc. Files Prospectus for $1.74 Million Public Offering of Common Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2554772643","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554772643?lang=en_us&edition=fundamental","pubTime":"2025-07-28 21:30","pubTimestamp":1753709409,"startTime":"0","endTime":"0","summary":"Tharimmune Inc., a clinical-stage biotechnology company focused on therapies in immunology and inflammation, has announced the pricing of a registered direct public offering aimed at raising approximately $1.74 million. The offering includes 414,331 shares of Common Stock and 559,910 pre-funded warrants to acquire shares of Common Stock, along with 974,241 warrants to acquire shares of Common Stock at an exercise price of $1.66 per share. The securities are offered at $1.786 per unit, following a Securities Purchase Agreement. A preliminary prospectus supplement and accompanying prospectus have been filed with the U.S. Securities and Exchange Commission , with a final prospectus supplement to follow. President Street Global, LLC is serving as the exclusive placement agent for the offering, which is expected to close around July 25, 2025, contingent on customary closing conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL3GBdWp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2553422207","title":"Tharimmune Inc. Announces $1.74 Million Registered Direct Public Offering of Common Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2553422207","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553422207?lang=en_us&edition=fundamental","pubTime":"2025-07-24 10:15","pubTimestamp":1753323340,"startTime":"0","endTime":"0","summary":"Tharimmune Inc., a clinical-stage biotechnology company focused on developing therapies in immunology and inflammation, has announced the pricing of a registered direct public offering of its securities, expected to raise approximately $1.74 million. The offering comprises 414,331 shares of common stock and 559,910 pre-funded warrants, along with 974,241 warrants to acquire shares of common stock at an exercise price of $1.66 per share. These securities are priced at $1.786 per unit. The net proceeds from this offering will be allocated for working capital and general corporate purposes. President Street Global, LLC is acting as the exclusive placement agent for the offering, which is anticipated to close around July 25, 2025, pending customary closing conditions. The offering is conducted under a shelf registration statement previously filed with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL4PXs1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2546258075","title":"Tharimmune Inc. Announces Immediate Resignation of Board Member Kelly Anderson","url":"https://stock-news.laohu8.com/highlight/detail?id=2546258075","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546258075?lang=en_us&edition=fundamental","pubTime":"2025-06-25 04:16","pubTimestamp":1750796163,"startTime":"0","endTime":"0","summary":"Tharimmune Inc. has announced a change in its management with the resignation of Kelly Anderson from the Board of Directors. The resignation was effective immediately on June 22, 2025, and was due to personal reasons.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL6NchgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2545251404","title":"CEO Sireesh Appajosyula Reports Acquisition of Common Shares in Tharimmune Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2545251404","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545251404?lang=en_us&edition=fundamental","pubTime":"2025-06-24 07:31","pubTimestamp":1750721503,"startTime":"0","endTime":"0","summary":"Sireesh Appajosyula, Chief Executive Officer of Tharimmune Inc., reported an acquisition of common shares of Tharimmune Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL5zYQ8d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CEO Sireesh Appajosyula Reports Acquisition of Common Shares in Tharimmune Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2544812559","title":"Tharimmune Inc. Announces $2.5 Million Private Placement to Fund Clinical Development and Working Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2544812559","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544812559?lang=en_us&edition=fundamental","pubTime":"2025-06-20 18:06","pubTimestamp":1750413980,"startTime":"0","endTime":"0","summary":"Tharimmune Inc. has announced a private placement agreement with accredited individual and institutional investors to raise approximately $2.5 million. The company will issue 1,551,351 shares of common stock, pre-funded warrants for 137,838 shares, Series A warrants for 1,689,189 shares at $1.29 per share, and Series B warrants for 844,572 shares at $3.00 per share. The transaction, expected to close on June 20, 2025, pending customary conditions, will see President Street Global acting as the exclusive placement agent. The funds will support Tharimmune's clinical development and working capital needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL3wDzlb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2544626959","title":"Tharimmune Inc. Announces Key Leadership Appointments, Names Sireesh Appajosyula as CEO and James Gordon Liddy to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2544626959","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544626959?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:11","pubTimestamp":1750162291,"startTime":"0","endTime":"0","summary":"Tharimmune Inc., a biotechnology company focusing on therapeutic candidates for inflammation and immunology, has announced key appointments to its executive leadership and board. Sireesh Appajosyula has been appointed as Chief Executive Officer, transitioning from his previous role as Chief Operating Officer. Vincent LoPriore has been named Executive Chairman of the Board, having served as a board member since April 2025. Additionally, James Gordon Liddy has joined the Board of Directors. These changes aim to advance the company's strategic initiatives and pipeline development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 17, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL6qfDHn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2544988619","title":"Tharimmune Inc. Announces Resignation of CFO Don Kim Due to Personal Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2544988619","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544988619?lang=en_us&edition=fundamental","pubTime":"2025-06-17 04:16","pubTimestamp":1750104996,"startTime":"0","endTime":"0","summary":"Tharimmune Inc. announced a change in its management team with the resignation of Don Kim from his position as Chief Financial Officer. The resignation is effective immediately and was due to personal reasons.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL9HF9rG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2542864558","title":"BRIEF-Tharimmune - Randy Milby Resigns As CEO And Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2542864558","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542864558?lang=en_us&edition=fundamental","pubTime":"2025-06-12 05:33","pubTimestamp":1749677593,"startTime":"0","endTime":"0","summary":"BRIEF-Tharimmune - Randy Milby Resigns As CEO And Board MemberJune 11  - Tharimmune Inc THAR.O:THARIMMUNE - RANDY MILBY RESIGNS AS CEO AND BOARD MEMBER - SEC FILINGTHARIMMUNE INC - SIREESH APPAJOSYULA APPOINTED AS CEO - SEC FILINGFurther company coverage: THAR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nFWN3SE0DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2542588345","title":"Tharimmune Inc. Announces Leadership Changes: Sireesh Appajosyula Appointed as CEO, James Gordon Liddy Joins Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2542588345","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542588345?lang=en_us&edition=fundamental","pubTime":"2025-06-12 05:30","pubTimestamp":1749677432,"startTime":"0","endTime":"0","summary":"Tharimmune Inc. has announced changes in its management team, effective June 11, 2025. Randy Milby has resigned from his roles as Chief Executive Officer and member of the Board of Directors, citing personal reasons. Sireesh Appajosyula has been appointed as the new Chief Executive Officer. Additionally, James Gordon Liddy has joined the Board of Directors, and Mr. LoPriore has been appointed as the Executive Chairman of the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2025, and is solely responsible for the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDLkF6fS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2542434057","title":"Tharimmune Inc. Held Its Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542434057","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542434057?lang=en_us&edition=fundamental","pubTime":"2025-06-11 04:40","pubTimestamp":1749588005,"startTime":"0","endTime":"0","summary":"Tharimmune Inc. held its Annual Meeting of Stockholders on June 10, 2025. At the meeting, all seven nominees for director were elected. The appointment of Rosenberg Rich Baker Berman P.A. as the independent registered public accounting firm for the fiscal year ended December 31, 2025, was ratified and approved. Additionally, the Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan was approved by the stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2Y2SCj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2536668911","title":"Tharimmune Inc. Appoints Counter-Terrorism Expert James Gordon Liddy as Strategic Advisor for Opioid Defense Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2536668911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536668911?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:03","pubTimestamp":1747656180,"startTime":"0","endTime":"0","summary":"Tharimmune Inc., a clinical-stage biopharmaceutical company, has appointed James Gordon Liddy, a retired US Navy SEAL and counter-terrorism expert, as a strategic advisor. Liddy will provide guidance as Tharimmune advances the development of TH104, a program focused on protecting military personnel and first responders from high-potency opioid exposure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via ACCESS Newswire  on May 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL3WbHcb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2536274340","title":"Director Sanam Parikh Reports Acquisition of Common Shares in Tharimmune Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536274340","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536274340?lang=en_us&edition=fundamental","pubTime":"2025-05-17 04:16","pubTimestamp":1747426578,"startTime":"0","endTime":"0","summary":"Sanam Parikh, a director at Tharimmune Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL1C9Bkd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2534278295","title":"Tharimmune Q1 EPS $(0.99) Up From $(2.55) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2534278295","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534278295?lang=en_us&edition=fundamental","pubTime":"2025-05-12 21:13","pubTimestamp":1747055604,"startTime":"0","endTime":"0","summary":"Tharimmune (NASDAQ:THAR) reported quarterly losses of $(0.99) per share. This is a 61.18 percent increase over losses of $(2.55) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45346969/tharimmune-q1-eps-0-99-up-from-2-55-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR"],"gpt_icon":0},{"id":"2534465630","title":"BRIEF-Tharimmune Inc - Appoints Vincent Lopriore As Executive Chairman - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534465630","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534465630?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:06","pubTimestamp":1746824799,"startTime":"0","endTime":"0","summary":"BRIEF-Tharimmune Inc - Appoints Vincent Lopriore As Executive Chairman - SEC FilingTharimmune Inc THAR.O:THARIMMUNE INC - APPOINTS VINCENT LOPRIORE AS EXECUTIVE CHAIRMAN - SEC FILINGSource text: [ID:n0001641172-25-009480]Further company coverage: THAR.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nFWN3RH2RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2531703172","title":"Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531703172","media":"ACCESS Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531703172?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:01","pubTimestamp":1746014460,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc.,   a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, increasing the Tharimmune Board to nine Directors. As reported in a Form 8-K filed on April 25, 2025, Directors Leonard Mazur and Lynne Bui, M.D. have notified the Board that they will not seek re-election at the Company's 2025 Annual Meeting of Stockholders on June 10, at which time the size of the Board will decline to seven Directors.Gary Stetz is a seasoned financial executive with over 35 years of experience across accounting, finance, busin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-appoints-clay-kahler-gary-120100597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2531264798","title":"Tharimmune Inc. Expands Board to Nine Members, Appoints Clay Kahler and Gary Stetz","url":"https://stock-news.laohu8.com/highlight/detail?id=2531264798","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531264798?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:26","pubTimestamp":1745875612,"startTime":"0","endTime":"0","summary":"Tharimmune Inc. has announced changes to its Board of Directors, increasing the number of board members to nine. The company has appointed Clay Kahler and Gary Stetz as new members of the Board, effective April 28, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nNDL8mv58v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2530049554","title":"Tharimmune announces FDA feedback on TH104 for prophylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2530049554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530049554?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:39","pubTimestamp":1745843941,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) announced feedback from the U.S. Food and Drug Administration regarding TH104. The agency confirmed that no additional clinical t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-announces-fda-feedback-on-th104-for-prophylaxis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-announces-fda-feedback-on-th104-for-prophylaxis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THAR"],"gpt_icon":0},{"id":"2527448587","title":"Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448587","media":"ACCESS Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448587?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:00","pubTimestamp":1744722000,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. , a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, to its Board of Directors, increasing the size of the Board to seven Directors.This appointment strengthens Tharimmune's strategic leadership and will support the company's next phase of growth and product development. It also underscores Tharimmune's commitment to enhancing its leadership team with experienced financial professionals as the company advances key clinical programs, deepens its licensing relationships and builds a pipeline for long-term, sustainable growth.About Vincent LoPrioreMr. LoPriore is a seasoned financial professional with more than 30 years of experience in investment banking, private placements and institutional capital markets. He began his career at Oppenheimer & Co. and sub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-strengthens-strategic-leadership-appointment-130000133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","THAR","BK4139"],"gpt_icon":0},{"id":"2525040436","title":"Tharimmune Reports Preclinical Data for Dual-Target Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2525040436","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525040436?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:59","pubTimestamp":1744037964,"startTime":"0","endTime":"0","summary":"Tharimmune  reported Monday preclinical data from its expanded pipeline featuring dual-target biologics HS1940 and HS3215, which it says was \"positive.\"HS1940 is designed to bind to both programmed death-1, or PD-1, and vascular endothelial growth factor, or VEGF, potentially improving treatment outcomes for various cancers. HS3215 targets human epidermal growth factor receptors 2 and 3, or HER2 and HER3, key proteins involved in cancer growth. HS1940 and HS3215 were developed using Tharimmune's antibody engineering platform, EpiClick Technology, the company said.The company also said it aims to further improve the binding characteristics of HS1940 and present more data at future conferences, with plans to begin investigational new drug, or IND-enabling studies in 2025. Tharimmune also said it is conducting preclinical studies on HS3215 and plans to advance it into clinical trials after IND-enabling studies.Shares of Tharimmune were down nearly 7% in recent trading.Price: 1.10, Change:","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["THAR","BK4139"],"gpt_icon":0},{"id":"2525045439","title":"Tharimmune announces preclinical data from expanded pipeline with HS1940","url":"https://stock-news.laohu8.com/highlight/detail?id=2525045439","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525045439?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:20","pubTimestamp":1744032038,"startTime":"0","endTime":"0","summary":"Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to bot...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tharimmune-announces-preclinical-data-from-expanded-pipeline-with-hs1940?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tharimmune-announces-preclinical-data-from-expanded-pipeline-with-hs1940?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THAR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/THAR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-25","symbol":"THAR","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742875200000,"reportTimeType":"post","actualEps":-2.02},{"market":"US","date":"2024-08-09","symbol":"THAR","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"","actualEps":-2.42},{"market":"US","date":"2024-05-28","symbol":"THAR","defaultRemindTime":1716903000000,"type":"split","dateTimestamp":1716868800000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-05-09","symbol":"THAR","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-0.19},{"date":"2024-02-23","symbol":"THAR","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708678800000,"name":null,"time":"Pre-Market","dateTimestamp":1708664400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"THAR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"THAR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1737604800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/THAR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"THAR","date":"2025-07-30","current":-0.453093,"percent":0.193396,"low":-0.627566,"twenty":-0.448155,"median":-0.309629,"eighty":-0.251206,"high":-0.078899,"avg":-0.329345,"sd":0.11835,"marketCap":5656032},"quantilePoints":[{"date":"2023-09-29","current":-0.382876,"twenty":-0.507054,"median":-0.396691,"eighty":-0.388402,"marketCap":3414917},{"date":"2023-10-05","current":-0.371034,"twenty":-0.396296,"median":-0.39077,"eighty":-0.38406,"marketCap":3309301},{"date":"2023-10-10","current":-0.365113,"twenty":-0.395507,"median":-0.388797,"eighty":-0.373639,"marketCap":3256493},{"date":"2023-10-19","current":-0.400638,"twenty":-0.396296,"median":-0.385837,"eighty":-0.371823,"marketCap":3573340},{"date":"2023-10-27","current":-0.354061,"twenty":-0.395901,"median":-0.382876,"eighty":-0.367481,"marketCap":3157918},{"date":"2023-11-02","current":-0.314984,"twenty":-0.394717,"median":-0.375178,"eighty":-0.354061,"marketCap":2809385},{"date":"2023-11-10","current":-0.37416,"twenty":-0.396691,"median":-0.374981,"eighty":-0.345575,"marketCap":3222178},{"date":"2023-11-17","current":-0.366027,"twenty":-0.394717,"median":-0.374571,"eighty":-0.354061,"marketCap":3152131},{"date":"2023-11-24","current":-0.23385,"twenty":-0.395112,"median":-0.373042,"eighty":-0.340009,"marketCap":2013859},{"date":"2023-12-01","current":-0.246337,"twenty":-0.391559,"median":-0.36684,"eighty":-0.303758,"marketCap":2121398},{"date":"2023-12-08","current":-0.177715,"twenty":-0.389586,"median":-0.365113,"eighty":-0.2671,"marketCap":1530437},{"date":"2023-12-15","current":-0.142524,"twenty":-0.386603,"median":-0.352622,"eighty":-0.21331,"marketCap":1227380},{"date":"2023-12-22","current":-0.155427,"twenty":-0.384688,"median":-0.345575,"eighty":-0.188612,"marketCap":1338501},{"date":"2023-12-29","current":-0.146629,"twenty":-0.383782,"median":-0.317747,"eighty":-0.176783,"marketCap":1262737},{"date":"2024-01-05","current":-0.146659,"twenty":-0.38276,"median":-0.312306,"eighty":-0.157175,"marketCap":1262989},{"date":"2024-01-12","current":-0.139005,"twenty":-0.38091,"median":-0.292008,"eighty":-0.148917,"marketCap":1197074},{"date":"2024-01-19","current":-0.114078,"twenty":-0.375376,"median":-0.280942,"eighty":-0.146629,"marketCap":982409},{"date":"2024-01-26","current":-0.133403,"twenty":-0.374981,"median":-0.23385,"eighty":-0.14311,"marketCap":1148838},{"date":"2024-02-02","current":-0.127861,"twenty":-0.37416,"median":-0.20534,"eighty":-0.138301,"marketCap":1101106},{"date":"2024-02-09","current":-0.111585,"twenty":-0.371924,"median":-0.18314,"eighty":-0.129796,"marketCap":960942},{"date":"2024-02-16","current":-0.114019,"twenty":-0.371034,"median":-0.158301,"eighty":-0.127861,"marketCap":981904},{"date":"2024-02-23","current":-0.111145,"twenty":-0.367679,"median":-0.155427,"eighty":-0.121656,"marketCap":957154},{"date":"2024-03-01","current":-0.48475,"twenty":-0.37506,"median":-0.166843,"eighty":-0.12223,"marketCap":4517427},{"date":"2024-03-08","current":-0.465853,"twenty":-0.385872,"median":-0.188565,"eighty":-0.123227,"marketCap":4341332},{"date":"2024-03-15","current":-0.464846,"twenty":-0.39748,"median":-0.211982,"eighty":-0.126981,"marketCap":4331940},{"date":"2024-03-22","current":-0.557437,"twenty":-0.450736,"median":-0.23385,"eighty":-0.128799,"marketCap":5194806},{"date":"2024-03-28","current":-0.547624,"twenty":-0.468827,"median":-0.280942,"eighty":-0.129034,"marketCap":5103356},{"date":"2024-04-05","current":-0.579242,"twenty":-0.47694,"median":-0.299351,"eighty":-0.129034,"marketCap":5398007},{"date":"2024-04-12","current":-0.522329,"twenty":-0.488151,"median":-0.314984,"eighty":-0.129491,"marketCap":4867635},{"date":"2024-04-19","current":-0.477811,"twenty":-0.486603,"median":-0.348379,"eighty":-0.13196,"marketCap":4452767},{"date":"2024-04-26","current":-0.45669,"twenty":-0.485414,"median":-0.359587,"eighty":-0.135532,"marketCap":4255940},{"date":"2024-05-03","current":-0.477432,"twenty":-0.482784,"median":-0.366433,"eighty":-0.137304,"marketCap":4449231},{"date":"2024-05-10","current":-0.518662,"twenty":-0.485414,"median":-0.371924,"eighty":-0.137996,"marketCap":4833456},{"date":"2024-05-17","current":-0.488448,"twenty":-0.487514,"median":-0.375178,"eighty":-0.138723,"marketCap":4340799},{"date":"2024-05-24","current":-0.434206,"twenty":-0.489085,"median":-0.382876,"eighty":-0.14006,"marketCap":3858750},{"date":"2024-05-31","current":-0.396974,"twenty":-0.487825,"median":-0.388797,"eighty":-0.141468,"marketCap":3527876},{"date":"2024-06-07","current":-0.451939,"twenty":-0.486699,"median":-0.395704,"eighty":-0.142758,"marketCap":4016347},{"date":"2024-06-14","current":-0.295417,"twenty":-0.486079,"median":-0.392744,"eighty":-0.143233,"marketCap":2625343},{"date":"2024-06-21","current":-0.276843,"twenty":-0.48475,"median":-0.386969,"eighty":-0.143726,"marketCap":2460277},{"date":"2024-06-28","current":-0.285687,"twenty":-0.484266,"median":-0.384008,"eighty":-0.144206,"marketCap":2538880},{"date":"2024-07-05","current":-0.293648,"twenty":-0.483128,"median":-0.378835,"eighty":-0.145162,"marketCap":2609622},{"date":"2024-07-12","current":-0.336103,"twenty":-0.481172,"median":-0.37416,"eighty":-0.146207,"marketCap":2986917},{"date":"2024-07-15","current":-0.339198,"twenty":-0.48087,"median":-0.373042,"eighty":-0.146313,"marketCap":3014428},{"date":"2024-08-02","current":-0.39802,"twenty":-0.480567,"median":-0.37416,"eighty":-0.146418,"marketCap":3537173},{"date":"2024-08-09","current":-0.357356,"twenty":-0.479583,"median":-0.371479,"eighty":-0.146647,"marketCap":3175790},{"date":"2024-08-16","current":-0.388311,"twenty":-0.47931,"median":-0.367704,"eighty":-0.147503,"marketCap":3446280},{"date":"2024-08-23","current":-0.383133,"twenty":-0.478979,"median":-0.3683,"eighty":-0.148084,"marketCap":3400329},{"date":"2024-08-30","current":-0.3621,"twenty":-0.478193,"median":-0.368895,"eighty":-0.150559,"marketCap":3213656},{"date":"2024-09-06","current":-0.374966,"twenty":-0.47771,"median":-0.368895,"eighty":-0.152319,"marketCap":3327842},{"date":"2024-09-13","current":-0.387016,"twenty":-0.477508,"median":-0.371479,"eighty":-0.153668,"marketCap":3434792},{"date":"2024-09-20","current":-0.387573,"twenty":-0.477179,"median":-0.37416,"eighty":-0.156013,"marketCap":3439732},{"date":"2024-09-27","current":-0.318415,"twenty":-0.476049,"median":-0.370611,"eighty":-0.157456,"marketCap":2825949},{"date":"2024-10-04","current":-0.288644,"twenty":-0.474874,"median":-0.368895,"eighty":-0.165134,"marketCap":2561734},{"date":"2024-10-11","current":-0.263637,"twenty":-0.474587,"median":-0.367652,"eighty":-0.176316,"marketCap":2339794},{"date":"2024-10-18","current":-0.304177,"twenty":-0.472752,"median":-0.367031,"eighty":-0.182055,"marketCap":2699586},{"date":"2024-10-25","current":-0.259599,"twenty":-0.469988,"median":-0.36557,"eighty":-0.188659,"marketCap":2303953},{"date":"2024-10-31","current":-0.443968,"twenty":-0.46923,"median":-0.363606,"eighty":-0.192108,"marketCap":3940246},{"date":"2024-11-08","current":-0.314532,"twenty":-0.469028,"median":-0.3621,"eighty":-0.207997,"marketCap":2791486},{"date":"2024-11-15","current":-0.305403,"twenty":-0.46859,"median":-0.361023,"eighty":-0.220423,"marketCap":3313862},{"date":"2024-11-22","current":-0.357444,"twenty":-0.468401,"median":-0.359587,"eighty":-0.228864,"marketCap":3878556},{"date":"2024-11-29","current":-0.28486,"twenty":-0.468199,"median":-0.357833,"eighty":-0.23385,"marketCap":3090956},{"date":"2024-12-06","current":-0.278012,"twenty":-0.466808,"median":-0.355708,"eighty":-0.23385,"marketCap":3016655},{"date":"2024-12-13","current":-0.298555,"twenty":-0.465853,"median":-0.352068,"eighty":-0.239263,"marketCap":3239560},{"date":"2024-12-20","current":-0.287599,"twenty":-0.465417,"median":-0.349391,"eighty":-0.246337,"marketCap":3120677},{"date":"2024-12-27","current":-0.294447,"twenty":-0.465417,"median":-0.343978,"eighty":-0.247606,"marketCap":3194979},{"date":"2025-01-03","current":-0.280751,"twenty":-0.465265,"median":-0.340267,"eighty":-0.248902,"marketCap":3046375},{"date":"2025-01-10","current":-0.297186,"twenty":-0.465036,"median":-0.335817,"eighty":-0.250096,"marketCap":3224700},{"date":"2025-01-17","current":-0.273904,"twenty":-0.46288,"median":-0.332711,"eighty":-0.251506,"marketCap":2972074},{"date":"2025-01-24","current":-0.295816,"twenty":-0.459788,"median":-0.324576,"eighty":-0.253179,"marketCap":3209839},{"date":"2025-01-31","current":-0.271165,"twenty":-0.458942,"median":-0.322298,"eighty":-0.256285,"marketCap":2942353},{"date":"2025-02-07","current":-0.367119,"twenty":-0.457712,"median":-0.324576,"eighty":-0.25649,"marketCap":3983531},{"date":"2025-02-14","current":-0.338605,"twenty":-0.457135,"median":-0.332752,"eighty":-0.257766,"marketCap":3674130},{"date":"2025-02-21","current":-0.332011,"twenty":-0.45669,"median":-0.334163,"eighty":-0.259599,"marketCap":3602581},{"date":"2025-02-28","current":-0.258409,"twenty":-0.45669,"median":-0.332711,"eighty":-0.258409,"marketCap":2803941},{"date":"2025-03-07","current":-0.279794,"twenty":-0.452773,"median":-0.327411,"eighty":-0.258409,"marketCap":3035992},{"date":"2025-03-14","current":-0.258409,"twenty":-0.451939,"median":-0.323592,"eighty":-0.257308,"marketCap":2803941},{"date":"2025-03-21","current":-0.27623,"twenty":-0.447209,"median":-0.318081,"eighty":-0.256285,"marketCap":2997317},{"date":"2025-03-28","current":-0.235121,"twenty":-0.446876,"median":-0.316359,"eighty":-0.256285,"marketCap":2867904},{"date":"2025-04-04","current":-0.216104,"twenty":-0.443968,"median":-0.314758,"eighty":-0.253062,"marketCap":2635941},{"date":"2025-04-11","current":-0.183256,"twenty":-0.434206,"median":-0.310649,"eighty":-0.250909,"marketCap":2235278},{"date":"2025-04-17","current":-0.190171,"twenty":-0.43272,"median":-0.309629,"eighty":-0.247606,"marketCap":2319628},{"date":"2025-04-25","current":-0.208324,"twenty":-0.428819,"median":-0.307528,"eighty":-0.235121,"marketCap":2541047},{"date":"2025-05-02","current":-0.267969,"twenty":-0.427212,"median":-0.306444,"eighty":-0.235121,"marketCap":3268567},{"date":"2025-05-09","current":-0.257596,"twenty":-0.421057,"median":-0.305275,"eighty":-0.235121,"marketCap":3142041},{"date":"2025-05-16","current":-0.223829,"twenty":-0.40927,"median":-0.304177,"eighty":-0.235121,"marketCap":2794097},{"date":"2025-05-23","current":-0.292009,"twenty":-0.404831,"median":-0.304105,"eighty":-0.236223,"marketCap":3645195},{"date":"2025-05-30","current":-0.315455,"twenty":-0.404174,"median":-0.304105,"eighty":-0.238157,"marketCap":3937875},{"date":"2025-06-06","current":-0.321849,"twenty":-0.402002,"median":-0.304798,"eighty":-0.241659,"marketCap":4017697},{"date":"2025-06-13","current":-0.292009,"twenty":-0.399067,"median":-0.305275,"eighty":-0.243561,"marketCap":3645195},{"date":"2025-06-20","current":-0.304798,"twenty":-0.397602,"median":-0.304972,"eighty":-0.244794,"marketCap":3804839},{"date":"2025-06-27","current":-0.375157,"twenty":-0.396861,"median":-0.305146,"eighty":-0.246971,"marketCap":4683145},{"date":"2025-07-03","current":-0.39645,"twenty":-0.396917,"median":-0.305471,"eighty":-0.248249,"marketCap":4948952},{"date":"2025-07-11","current":-0.5972,"twenty":-0.404301,"median":-0.306569,"eighty":-0.249668,"marketCap":7454942},{"date":"2025-07-18","current":-0.556712,"twenty":-0.425538,"median":-0.306929,"eighty":-0.250279,"marketCap":6949522},{"date":"2025-07-25","current":-0.516223,"twenty":-0.442016,"median":-0.309442,"eighty":-0.250983,"marketCap":6444102},{"date":"2025-07-30","current":-0.453093,"twenty":-0.448155,"median":-0.309629,"eighty":-0.251206,"marketCap":5656032}],"updateTime":1753972619828}}}